| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2144176 | Lung Cancer | 2007 | 6 Pages |
Abstract
The results suggest that the combination of irinotecan (CPT-11) and carboplatin is active and well tolerable in patients with limited disease SCLC who were not suitable for concurrent chemotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Eckart Laack, Ina Thöm, Andreas Krüll, Walburga Engel-Riedel, Thomas Müller, Christoph MeiÃner, Heinz Dürk, Jürgen Fischer, Sylvia Gütz, Cornelius Kortsik, Matthias Elbers, Gunter Schuch, Birte Andritzky, Michael Görn, Iris Burkholder,